Important note

This AI stock analysis for Calidi Biotherapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Calidi Biotherapeutics - AI Stock Analysis

Analysis generated August 23, 2024

Calidi Biotherapeutics is an innovative biopharmaceutical company focused on the development of cutting-edge immunotherapy treatments. The company aims to harness the power of the immune system to combat cancer and other serious diseases. Despite being a front-runner in its field, recent trends and financial data provide mixed signals about its current market standing and future prospects.

Fundamental Analysis

Revenue: The revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability but also highlighting a potential issue in generating revenue. More concerning is that this figure represents a 100.00% decrease compared to the same quarter last year, which may be a red flag for potential investors.

Net Income: The net income for the last quarter was $5.8M. This shows an increase of 20.18% compared to the quarter before it, indicating short-term growth. Additionally, there is a significant 53.87% increase compared to the same quarter last year, suggesting strong year-over-year performance.

EBITDA: The EBITDA for the last quarter was $0. This figure is consistent with the previous quarter and the same quarter last year, highlighting the stability of operating profits but also indicating no recent growth in this critical financial metric.

Technical Analysis

Stock Price: Today's stock price stands at $1.15, reflecting a noticeable decrease of 32.35% compared to a month ago. This short-term bearish trend could be concerning for immediate prospects. Compared to a year ago, the stock has plummeted by 98.48%, raising significant concerns for long-term investors.

SMA10: The current SMA10 is $1.50, which is lower than the previous SMA10 of $1.55. This decrement indicates a potential downward trend in price movement.

RSI: The RSI is at 54.4, which falls within the neutral zone. An RSI within this range suggests that there is no immediate overbought or oversold condition, indicating potential price stability in the near term.

Alternative Data Analysis

Job Postings and Employee Sentiment: Calidi Biotherapeutics has zero open positions according to data from popular job boards. The number of open positions has remained stable over the last couple of months, suggesting a stable staffing situation.

Customer Acquisition: The company reports an estimated 2,000 visitors to its webpage, representing a decline of 67% over the last couple of months. This downturn is worrisome as it may point to a loss in potential customer interest.

Customer Engagement: The company has 59 followers on its Twitter page, reflecting an 18% increase over the last couple of months. This uptick in social media followers indicates a growing interest or better marketing outreach.

AI Score: Based on AltIndex’s AI score, which integrates fundamental, technical, and alternative data analysis, Calidi Biotherapeutics has a score of 63. This score falls within the 'buy' signal range, suggesting a potential positive outlook as advised by AI-based predictive models.

Conclusion and Recommendation

Calidi Biotherapeutics presents a mixed bag for potential investors. While the company shows strong year-over-year growth in net income (53.87% increase) and stable EBITDA, its consistent revenue of $0 and a massive decrease in stock price over the past year (98.48%) cast a shadow on its long-term viability. The downward trend indicated by its SMA10 and a stable RSI suggest short-term bearish sentiments. Moreover, the company's declining web traffic is concerning, although increasing social media engagement offers a glimmer of hope.

The AltIndex AI score of 63 suggests a ‘buy’ signal, but this should be weighed cautiously against the broader financial and market indicators. Based on the data provided, potential investors should approach with caution. In summary, while there are some encouraging signs, the significant revenue and stock price concerns necessitate a highly scrutinous approach before making an investment decision.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.